Trade name approval for a new topical foam to treat psoriasis

As of February 2019, adults with plaque psoriasis have a new topical option for their treatment with the introduction of Lexette (halobetasol propionate, 0.05%) . On April 30, 2019, the U.S. Food and Drug Administration (FDA) approved the trade name Lexette (halobetasol propionate, 0.05%), for the foam-based corticosteroid. 

Manufactured by Australia-based Mayne Pharma, Lexette is a new formulation of halobetasol, which can reduce itching, scaling, redness and swelling associated with psoriasis. The topical is designed to be used by applying a thin layer on affected areas of the skin and rubbed into the skin twice a day for as long as prescribed by your health care provider. 

Jeffrey M. Weinberg, M.D., dermatologist at Mount Sinai in New York and NPF medical board member, says that now halobetasol can be delivered via a foam, the effective corticosteroid can expand to more use cases and patients. 

“This is a useful addition to our treatment armamentarium,” says Weinberg. “Halobetasol has been a go-to product for the treatment of psoriasis for over 20 years. A foam version of this compound gives clinicians the versatility to use it in additional areas of the body, including the scalp and hair-bearing areas.”

More than $19 million has been invested in psoriatic disease research since 1987 thanks to NPF grants and fellowships. This funding has had a direct impact on the research and development of new treatment options. NPF also helps connect patients with clinical trials so that more therapies can be tested and approved.

Once a drug receives FDA approval, NPF provides the latest information on treatment options to health care providers and ensures you have access to the best health care possible

Learn more about your treatment options
The NPF Patient Navigation Center can assist you in information on the latest treatments, including Lexette foam, and can help you find the right health care provider in your area. 


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

NPF Early Career Research Grant recipient Holly Anderton chats about how she...
image of foam with the words "FDA approved"
Lexette, a topical corticosteroid foam, aims to reduce plaques.
FDA Approved Topical
The latest topical lotion aims to reduce plaque and clear your skin.
Pstamp Out Portland
Team NPF is putting the fun in fundraising with a series of Pstamp Out events...
Philip Mease in office in front of Seattle skyline
From barefoot doctor to world-renowned rheumatologist and researcher – meet our...
Anthony Getschman
NPF Early Career Research Grant recipient Anthony Getschman discusses his...
Clockwise from left, Brittany Duffy-Goche, Marc Boas, Pete Redding, Tami Seretti, Lisa Bayautet
How patients descended on our nation’s capitol for NPF’s annual fly-in.
headshot of Nsarg Shah
This chemical engineer approaches psoriatic arthritis from a whole new angle.
FDA Approval Skyrizi
The latest interleukin-23 inhibitor is aimed at adults with moderate-to-severe...